Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Anna R Hayden, MD, Derrick G Lee, PhD, Diego Villa, MD, Alina S. Gerrie, MD MPH, David W. Scott, PhDMD, FRACP, FRCPA, Graham W Slack, MD, Laurie H Sehn, MD MPH, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2018) 132 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2018-99-111047

Published: 2018

Journal Articles

Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Kerry J Savage, BSc, MD MSc, Diego Villa, MD, David W. Scott, PhDMD, FRACP, FRCPA, Alina S. Gerrie, MD MPH, David J Ferguson, Fergus Cafferty, Graham W Slack, MD, Pedro Farinha, MD PhD, Brian Skinnider, Joseph M. Connors, MD, Laurie H Sehn, MD MPH

Blood (2018) 132 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2018-99-113675

Published: 2018

Journal Articles

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Anjali Silva, PhD MSc, BSc, Clementine Sarkozy, MD, Tracy Lackraj, PhD BSc, Anja Mottok, Vindi Jurinovic, MSc, Laurie H Sehn, MD MPH, Oliver Weigert, MD, Christian Steidl, MD, Robert Kridel, PhD MD

Blood (2018) 132 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2018-99-112689

Published: 2018

Journal Articles

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Blood (2018) 132 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2018-99-116750

Published: 2018

Journal Articles

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Hatem Alahwal, MPH, MBBS, Parv Chapani, Diego Villa, MD FRCPC, Yasser Abou Mourad, MD, Maryse Power, MD, Stephen H. Nantel, MD, David Sanford, MD, Gayatri Sreenivasan, BSc, MD, Heather J. Sutherland, MD PhD, Laurie H Sehn, MD MPH, Cynthia L. Toze, MD FRCPC, MSc, Raewyn Broady, MBChB, Kevin Song, MD, Paul Yenson, MD BSc, FRCPC, Alina S. Gerrie, MD MPH

Blood (2018) 132 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2018-99-114371

Published: 2018

Journal Articles

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2018-99-112010

Published: 2018

Journal Articles

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Christiane Pott, MD PhD, David Belada, MD PhD, Nathalie Danesi, PhD, Günter Fingerle-Rowson, MD PhD, John Gribben, MDDSc, Chris Harbron, MPhil, Eva Hoster, PhD, Brad S Kahl, MD, Kirsten Mundt, PhD, Catherine Sebban, MD, Laurie H Sehn, MD MPH, Bruce D. Cheson, MD

Blood (2015) 126 (23): 3978.

https://doi.org/10.1182/blood.V126.23.3978.3978

Published: 2015

Journal Articles

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Peter C Trask, PhD MPH, John Gribben, MDDSc, Natalie Dimier, Eva Kimby, MD PhD, Pieternella J Lugtenburg, MD PhD, Catherine Thieblemont, Elisabeth Wassner Fritsch, MD, Laurie H Sehn, MD MPH

Blood (2015) 126 (23): 1532.

https://doi.org/10.1182/blood.V126.23.1532.1532

Published: 2015

Journal Articles

Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD MPH, Edward L G Hardy, MD FRCPC, Karamjit K Gill, MD FRCPC, Abdulwahab J Al-Tourah, MBChB, FRCPC, Jesse Shustik, MD, Nicol A Macpherson, MDPhDFRCPC,, Adrian Yee, MD FRCPC, Wendy Lam, MD, Kerry J. Savage, MD MSc, Richard Klasa, MD CM, FRCP(C), Diego Villa, MDMPH, Alina S Gerrie, MD, Tamara Shenkier, MD, Graham W Slack, MD, Randy D. Gascoyne, MD, Francois Benard, MD, Don Wilson, MD, Peter Tonseth, MD, Joseph M Connors, MD

Blood (2014) 124 (21): 392.

https://doi.org/10.1182/blood.V124.21.392.392

Published: 2014

Journal Articles

Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Roopesh R. Kansara, MD, Tamara Shenkier, MD, Joseph M Connors, MD, Alina S. Gerrie, MD MPH, Richard Klasa, MD, Kerry J. Savage, MDMSc, Laurie H. Sehn, MD MPH, Diego Villa, MDMPH

Blood (2014) 124 (21): 3090.

https://doi.org/10.1182/blood.V124.21.3090.3090

Published: 2014

Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood (2014) 124 (21): 4457.

https://doi.org/10.1182/blood.V124.21.4457.4457

Published: 2014

Journal Articles

Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma

Stephen Parkin, MD, BSc, Joseph M. Connors, MD, Laurie H. Sehn, MD, MPH, Diego Villa, MD, MPH, Richard Klasa, MD, Alina S. Gerrie, MD, Randy D. Gascoyne, MD, Tamara Shenkier, MD, Cynthia L. Toze, MD, John D. Shepherd, MD, Kevin Song, MD, Kerry J. Savage, MD, MSc

Blood (2013) 122 (21): 4345.

https://doi.org/10.1182/blood.V122.21.4345.4345

Published: 2013

Journal Articles

The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas

Jean-Michel Lavoie, MD, CM, MEng, Joseph M. Connors, MD, Diego Villa, MD, MPH, Richard Klasa, MD, Tamara Shenkier, MD, Randy D. Gascoyne, MD, Alina S. Gerrie, MD, Laurie H. Sehn, MD, MPH, Kerry J. Savage, MD, MSc

Blood (2013) 122 (21): 1804.

https://doi.org/10.1182/blood.V122.21.1804.1804

Published: 2013

Journal Articles

The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience

Amrit Kahlon, MD, Graham W. Slack, MD, Yuhua Sun, MD, Richard Klasa, MD, Laurie H. Sehn, MD, MPH, Diego Villa, MD, MPH, Tamara Shenkier, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Kerry J. Savage, MD, MSc

Blood (2013) 122 (21): 4390.

https://doi.org/10.1182/blood.V122.21.4390.4390

Published: 2013

Journal Articles

Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC)

Katharine He Xing, MD, Amrit Kahlon, MD, Joseph M. Connors, MD, Brian Skinnider, MD, Randy D. Gascoyne, MD, Laurie H. Sehn, MD, MPH, Kerry J. Savage, MD, MSc, Graham W. Slack, MD, Tamara Shenkier, MD, Richard Klasa, MD, Alina S. Gerrie, MD, Diego Villa, MD, MPH

Blood (2013) 122 (21): 4369.

https://doi.org/10.1182/blood.V122.21.4369.4369

Published: 2013

Journal Articles

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

Blood (2013) 122 (21): 1788.

https://doi.org/10.1182/blood.V122.21.1788.1788

Published: 2013

Journal Articles

Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival

Daisuke Ennishi, MD, PhD, Fong Chun Chan, MSc, David W. Scott, MBChB PhD, Christoffer Hother, MD, PhD, Barbara Meissner, PhD, Merrill Boyle, B.Sc., Ryan D Morin, Laurie H. Sehn, MD, MPH, Marco A. Marra, PhD, Joseph M. Connors, MD, Christian Steidl, MD, Randy D. Gascoyne, MD

Blood (2013) 122 (21): 500.

https://doi.org/10.1182/blood.V122.21.500.500

Published: 2013

Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD

Blood (2012) 120 (21): 56.

https://doi.org/10.1182/blood.V120.21.56.56

Published: 2012

Journal Articles

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Laurie H. Sehn, MD, MPH, Andre Goy, MD, Fritz C. Offner, MD, PhD, Giovanni Martinelli, MD, Jonathan Friedberg, MD, Susan F. Lasserre, MSc, Gregg Fine, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 269.

https://doi.org/10.1182/blood.V118.21.269.269

Published: 2011

Journal Articles

Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors

Vivien Mak, MBBS FHKAM, Joseph M. Connors, MD, Richard Klasa, MD, Laurie H. Sehn, MD, MPH, Diego Villa, MD, MPH, Tamara Shenkier, MD, Mukesh Chhanabhai, MD, Randy D. Gascoyne, MD, Kerry J. Savage, MD MSc

Blood (2011) 118 (21): 96.

https://doi.org/10.1182/blood.V118.21.96.96

Published: 2011

NARROW

Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma

Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma

The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas

The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience

Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC)

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only